176 related articles for article (PubMed ID: 25304610)
21. Clearance of minimal residual disease after allogeneic stem cell transplantation and the prediction of the clinical outcome of adult patients with high-risk acute lymphoblastic leukemia.
Spinelli O; Peruta B; Tosi M; Guerini V; Salvi A; Zanotti MC; Oldani E; Grassi A; Intermesoli T; Micò C; Rossi G; Fabris P; Lambertenghi-Deliliers G; Angelucci E; Barbui T; Bassan R; Rambaldi A
Haematologica; 2007 May; 92(5):612-8. PubMed ID: 17488684
[TBL] [Abstract][Full Text] [Related]
22. The TAL1 complex targets the FBXW7 tumor suppressor by activating miR-223 in human T cell acute lymphoblastic leukemia.
Mansour MR; Sanda T; Lawton LN; Li X; Kreslavsky T; Novina CD; Brand M; Gutierrez A; Kelliher MA; Jamieson CH; von Boehmer H; Young RA; Look AT
J Exp Med; 2013 Jul; 210(8):1545-57. PubMed ID: 23857984
[TBL] [Abstract][Full Text] [Related]
23. The long-term results of childhood acute lymphoblastic leukemia at two centers from Turkey: 15 years of experience with the ALL-BFM 95 protocol.
Güneş AM; Oren H; Baytan B; Bengoa SY; Evim MS; Gözmen S; Tüfekçi O; Karapınar TH; Irken G
Ann Hematol; 2014 Oct; 93(10):1677-84. PubMed ID: 24863691
[TBL] [Abstract][Full Text] [Related]
24. MYCN is a novel oncogenic target in pediatric T-cell acute lymphoblastic leukemia.
Astolfi A; Vendemini F; Urbini M; Melchionda F; Masetti R; Franzoni M; Libri V; Serravalle S; Togni M; Paone G; Montemurro L; Bressanin D; Chiarini F; Martelli AM; Tonelli R; Pession A
Oncotarget; 2014 Jan; 5(1):120-30. PubMed ID: 24334727
[TBL] [Abstract][Full Text] [Related]
25. TAL1/SCL is downregulated upon histone deacetylase inhibition in T-cell acute lymphoblastic leukemia cells.
Cardoso BA; de Almeida SF; Laranjeira AB; Carmo-Fonseca M; Yunes JA; Coffer PJ; Barata JT
Leukemia; 2011 Oct; 25(10):1578-86. PubMed ID: 21647153
[TBL] [Abstract][Full Text] [Related]
26. Infrequent erythrophagocytosis by leukemic blasts in de novo T-lymphoblastic leukemia with SIL-TAL1: A rare pediatric case.
Li T; Su L; Li X; Zhang Y; Li L; Zhu J
Pediatr Blood Cancer; 2023 Oct; 70(10):e30544. PubMed ID: 37407425
[No Abstract] [Full Text] [Related]
27. Early T-cell precursor acute lymphoblastic leukaemia in children treated in AIEOP centres with AIEOP-BFM protocols: a retrospective analysis.
Conter V; Valsecchi MG; Buldini B; Parasole R; Locatelli F; Colombini A; Rizzari C; Putti MC; Barisone E; Lo Nigro L; Santoro N; Ziino O; Pession A; Testi AM; Micalizzi C; Casale F; Pierani P; Cesaro S; Cellini M; Silvestri D; Cazzaniga G; Biondi A; Basso G
Lancet Haematol; 2016 Feb; 3(2):e80-6. PubMed ID: 26853647
[TBL] [Abstract][Full Text] [Related]
28. RT/PCR detection of SIL-TAL-1 fusion mRNA in Chinese T-cell acute lymphoblastic leukemia (T-ALL).
Huang W; Kuang SQ; Huang QH; Dong S; Zhang T; Gu LJ; Ching LM; Chen SJ; Chang LC; Chen Z
Cancer Genet Cytogenet; 1995 May; 81(1):76-82. PubMed ID: 7773964
[TBL] [Abstract][Full Text] [Related]
29. SIL/TAL1 recombination in adult T-acute lymphoblastic leukemia and T-lymphoblastic lymphoma.
Kwong YL; Chan D; Liang R
Cancer Genet Cytogenet; 1995 Dec; 85(2):159-60. PubMed ID: 8548743
[No Abstract] [Full Text] [Related]
30. Clinical features and outcome of T-cell acute lymphoblastic leukemia in childhood with respect to alterations at the TAL1 locus: a Pediatric Oncology Group study.
Bash RO; Crist WM; Shuster JJ; Link MP; Amylon M; Pullen J; Carroll AJ; Buchanan GR; Smith RG; Baer R
Blood; 1993 Apr; 81(8):2110-7. PubMed ID: 8471769
[TBL] [Abstract][Full Text] [Related]
31. [Classical and molecular cytogenetic abnormalities in 124 pediatric patients with acute lymphoblastic leukemia].
Chai YH; Lü H; Li JQ; Lu J; Xiao PF; He YX; Shao XJ
Zhonghua Er Ke Za Zhi; 2007 Sep; 45(9):684-6. PubMed ID: 18021563
[TBL] [Abstract][Full Text] [Related]
32. TAL1 activation in T-cell acute lymphoblastic leukemia: a novel oncogenic 3' neo-enhancer.
Smith C; Goyal A; Weichenhan D; Allemand E; Mayakonda A; Toprak U; Riedel A; Balducci E; Manojkumar M; Pejkovska A; Mücke O; Sollier E; Bakr A; Breuer K; Lutsik P; Hermine O; Spicuglia S; Asnafi V; Plass C; Touzart A
Haematologica; 2023 May; 108(5):1259-1271. PubMed ID: 36632736
[TBL] [Abstract][Full Text] [Related]
33. Inferior outcomes of stage III T lymphoblastic lymphoma relative to stage IV lymphoma and T-acute lymphoblastic leukemia: long-term comparison of outcomes in the JACLS NHL T-98 and ALL T-97 protocols.
Kobayashi R; Takimoto T; Nakazawa A; Fujita N; Akazai A; Yamato K; Yazaki M; Deguchi T; Hashii Y; Kato K; Hatakeyama N; Horibe K; Hori H; Oda M;
Int J Hematol; 2014 Jun; 99(6):743-9. PubMed ID: 24803201
[TBL] [Abstract][Full Text] [Related]
34. A novel translocation t(1;5)(p32;q31) that was not associated with the TAL1 rearrangement in a case of T lymphoblastic leukemia/lymphoma.
Cho HS; Kim MK; Bae YK
Korean J Lab Med; 2009 Jun; 29(3):199-203. PubMed ID: 19571616
[TBL] [Abstract][Full Text] [Related]
35. HOX11L2 expression defines a clinical subtype of pediatric T-ALL associated with poor prognosis.
Ballerini P; Blaise A; Busson-Le Coniat M; Su XY; Zucman-Rossi J; Adam M; van den Akker J; Perot C; Pellegrino B; Landman-Parker J; Douay L; Berger R; Bernard OA
Blood; 2002 Aug; 100(3):991-7. PubMed ID: 12130513
[TBL] [Abstract][Full Text] [Related]
36. Suppression of super-enhancer-driven TAL1 expression by KLF4 in T-cell acute lymphoblastic leukemia.
Noura M; Matsuo H; Yasuda T; Tsuzuki S; Kiyoi H; Hayakawa F
Oncogene; 2024 Feb; 43(6):447-456. PubMed ID: 38102337
[TBL] [Abstract][Full Text] [Related]
37. Simultaneous rearrangements of TAL1 and LMO2 in T-cell acute lymphoblastic leukemia.
Kim HK; Lim JH; Koh KN; Chi HS; Seo EJ
Int J Lab Hematol; 2014 Oct; 36(5):e69-70. PubMed ID: 24330618
[No Abstract] [Full Text] [Related]
38. [A tal-1 deletion as real-time quantitative polymerase chain reaction target for detection of minimal residual disease in T-lineage acute lymphoblastic leukemia].
Wang L; Zhang LP; Li ZG; Cheng YF; Tian KG; Lu AD
Zhonghua Er Ke Za Zhi; 2005 Mar; 43(3):170-3. PubMed ID: 15833185
[TBL] [Abstract][Full Text] [Related]
39. Requirement for Lyl1 in a model of Lmo2-driven early T-cell precursor ALL.
McCormack MP; Shields BJ; Jackson JT; Nasa C; Shi W; Slater NJ; Tremblay CS; Rabbitts TH; Curtis DJ
Blood; 2013 Sep; 122(12):2093-103. PubMed ID: 23926305
[TBL] [Abstract][Full Text] [Related]
40. MAP3K7 is recurrently deleted in pediatric T-lymphoblastic leukemia and affects cell proliferation independently of NF-κB.
Cordas Dos Santos DM; Eilers J; Sosa Vizcaino A; Orlova E; Zimmermann M; Stanulla M; Schrappe M; Börner K; Grimm D; Muckenthaler MU; Kulozik AE; Kunz JB
BMC Cancer; 2018 Jun; 18(1):663. PubMed ID: 29914415
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
